Treatment potential for immunotherapy-induced cytokine release syndrome
Drug Discovery World
JANUARY 18, 2024
The results, together with the data from the recent LPS human challenge trial, further support the strategic expansion of the Phase II ready POLB 001 to treat and prevent cancer immunotherapy-induced CRS. Reductions were seen in all serum proinflammatory cytokines tested.
Let's personalize your content